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In the transformation of fibroblasts by defective sarcoma viruses, the role of the helper 
virus has usually been interpreted as the provision of virion proteins. These may include 
the internal structural components, the external glycoproteins, and/or the reverse 
transcriptase (1-4). The ease with which nonproducer, transformed cells can be isolated 
(5, 6) has suggested that the helper genome plays no role in transformation by defective 
sarcoma viruses and in certain cases direct examination of transformed cells has 
confirmed the absence of certain helper nucleic acid sequences (7, 8). Thus, we view 
fibroblast ransformation solely as a consequence of the action of a gene or genes of the 
defective virus, a view which is supported by the apparent independence of the avian src 
gene from the rest of the nondefective Rous sarcoma virus genome (9, t0). With this 
background we have been analyzing the helper specificity for transformation of lympho- 
cytes by the Abelson murine leukemia virus (A-MuLV).' 
A-MuLV, originally isolated from a tumor arising in a prednisolone-treated BALB/c 
mouse inoculated with Moloney murine leukemia virus (M-MuLV), induces a thymus- 
independent lymphoma 3-5 wk postinoculation (11). A-MuLV resembles rapidly trans- 
forming murine sarcoma viruses in its mode of replication on fibroblast cell lines. The 
virus stocks from A-MuLV-induced tumors contain a defective virus which transforms 
some fibrobtasts and an oncogenic thymic lymphoma helper virus, M-MuLV. The 
transforming component of A-MuLV can be obtained free of replicating helper virus by 
isolating nonproducer fibroblast cell lines (12). Several of these cell lines lack significant 
sequences of the helper virus genome (7, 8). 
A -MuLV is un ique  in that  it  a lso t rans forms lympho id  cel ls in v i t ro (13). A 
quant i ta t ive  semiso l id  cu l ture  sys tem which  mon i to rs  the  f requency of  t ransfor -  
mat ion  has  been developed (14). To ana lyze  the  role of  he lper  v i rus  in A -MuLV-  
induced t rans format ion ,  we tested the  oncogenic ac t iv i ty  and  the  t rans forming  
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NAOMI ROSENBERG AND DAVID BALTIMORE 
TAnLE I 
Origin of Helper Viruses 
1127 
Virus stock Abbreviation used 
Moloney murine leukemia virus, clone 1 (reference 18) 
Moloney murine leukemia virus, clone 2 
Friend murine leukemia virus (N-tropic), clone 13 
Friend murine leukemia virus (B-tropic), clone 10 
BALB/c endogenous virus WN1802N-C135 (references 19 and 20) 
Gross murine leukemia virus 
M-MuLV-1 
M-MuLV-2 
F-MuLV-N 
F-MuLV-B 
E-MuLV 
G-MuLV 
abi l i ty  of A -MuLV stocks prepared with  several  di f ferent he lper  v iruses.  For 
f ibroblasts,  al l  of the mur ine  ret rov i ruses  tested were equ iva lent ly  effective 
helpers and  A-MuLV stocks prepared wi th  helpers that  are h igh ly  oncogenic 
were found to be h igh ly  oncogenic in vivo and  to t rans form lymphoid  cells 
eff iciently. We were surpr ised,  however,  to f ind that  A -MuLV prepared with  
helpers that  are weakly  oncogenic a lone is very ineff ic ient as a t rans forming  
agent  e i ther  in vivo and  in vitro. This  resu l t  suggests that  the helper  v i rus  may 
play a more active role in  lympho id  cell t rans format ion  than  in  f ibroblast  
t rans format ion .  
Mater ia l s  and  Methods  
Cell Cultures. Most fibroblast cell cultures were maintained in Dulbecco's modified Eagle's 
medium (Grand Island Biological Co., Grand Island, N. Y.) supplemented with 10% calf serum 
(Microbiological Associates, Walkersville, Md.) (DME-CS). JLS-V9 and CCL64 mink lung cells 
were maintained in DME supplemented with 10% heat inactivated (at 56°C for 30 rain) fetal calf 
serum (Microbiological Associates) (DME-IFS). 5H cells, an A-MuLV-transformed nonproducer 
fibroblast clone, were derived by infecting JLS-V9 cells at a multiplicity of infection (moi) of 3 
focus-forming units (FFU) and 2 plaque-forming units (PFU) with A-MuLV(M-MuLV-1) (see 
Table I for a description ofthe helper viruses used). After a 1.5-h adsorption period, the cells were 
washed two times with phosphate-buffered saline (PBS) (200 rag/liter KC1, 200 rag/liter KH~PO,, 
100 mg/liter MgCI~. 6H,O, 8,000 rag/liter NaC1, 1,150 mg/liter Na~HPO4.2I-I~O), trypsinized for 7 
min at 37°C, and plated in microtiter wells at a concentration f 0.33 cells/well. Transformed 
clones were isolated 14 days later and screened for virus production by using infectivity and 
reverse transcriptase assays. 5H cells are morphologically transformed but supernates from these 
cells contain no detectable infectious virus or reverse transcriptase. The cells contain the A- 
MuLV genomes as demonstrated by rescue xperiments with M-MuLV-2. 
Lymphoid Cell Lines. A-MuLV-transformed lymphoid cell lines were derived by removing 
single foci from agarose transformation plates with a Pasteur pipette. The cells were transferred 
to 16-ram plastic wells (Coming Glass Works, Corning, N. Y.), suspended in 1 ml of RPMI-1640 
(Grand Island Biological Co.), supplemented with 20% heat inactivated fetal calf serum and 50 
~M 2-mercaptoethanol (Eastman Kodak Co., Rochester, N. Y.) (RPMI medium). Cultures were 
observed aily for growth and maintained at densities of 5 × 105-1 × 10 e cells/ml until the 
cultures grew vigorously, doubling every 12 h. The length of this adaptation period usually varied 
from 3 to 4 days to 1-2 wk. Once established, cells were paseaged at a 1:100 split ratio when they 
reached a density of 2.5-3.5 × 108 celts/ml, about every 3rd day. 
BR48 is an A-MuLV-transformed lymphoid nonproducer cell line derived from A-MuLV(M- 
MuLV-1)-infected C57BR/cdJ (Fv-1 ~n) bone marrow cells. 2M is another A-MuLV-transformed 
nonproducer cell line derived from A-MuLV(M-MuLV-2) infected BALB/c (Fv-1 b~b) bone marrow 
cells. Both of these cell lines contain the A-MuLV genome as demonstrated by recovery of 
oncogenic, transforming virus after M-MuLV-2 superinfection. 
L691 cells, a gift of Dr. Paul Arnstein, California State Department ofHealth, were derived 
from a radiation-induced thymoma in a C57L mouse (15). These cells express markers commonly 
associated with T-cell tumors uch as Thy-1, TL, and Lyt-4 antigens, and the enzyme terminal 
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1128 ABELSON VIRUS 
deoxynucleotidyl transferase (16, 17; A. Silverstone t al., unpublished results). No infectious 
ecotropie virus has been isolated from the cells, but xenotropic virus can be recovered by cocul- 
tivation of L691 cells with CCI~4 mink lung cells or other non-murine cell lines (15; N. Rosenberg 
and D. Baltimore, unpublished results). 
Virus Stocks. M-MuLV-I, M-MuLV-2, Friend-MuLV(F-MuLV)-N, Gross-MuLV(G-MuLV), 
G-MuLV,I, and E -MuLV were all grown as N/HI3T3 carrier cell cultures (Table I). F -MuLV-B 
was maintained as a BALB/3T3 carrier culture. M-MuLV- I  was originally isolated from JLS-Vll 
cells by end point dilution as previously described (18). M-MuLV-2 was isolated from M-MuLV- I  
by cloning NIHI3T3 cells a~er adsorption of virus at low multiplicity. E -MuLV was isolated by 
end point dilution of WN1802N (19) as previously described (20). G-MuLV,  originally obtained 
from Dr. Nancy Hopkins, M.I.T., was cloned by infecting NIH/3T3 cells at a moi of 0.3 PFU. After 
a 1.5-h adsorption period, the infected ceils were trypsinized and plated in microtiter plates at a 
concentration of 0.3 cells/well. 10 days later, all wells containing cells were assayed for virus 
production by the XC plaque assay (21). 2 of 51 clones released infectious virus, and one of these, 
G-MuLV-I, was selected for use in experiments. Cloned F -MuLV stocks originally obtained from 
Dr. Robert Eckner, Boston University School of Medicine, Boston, Mass. were a gift of Dr. Alfred 
Bothwell, M.LT. F -MuLV-N and F-MuLV-B were isolated by low moi and cloning of SC-I cells. 
C57BI/KaB (22), a clone of flbrotropic C57BI/6 virus, was a gift of Doctors Henry Kaplan and 
Alain Decl~ve, Stanford University, Stanford, Calif. 
A -MuLV stocks were prepared by superinfecting mass cultures of nonproducer flbroblast cells 
with helper virus. After a 2-h adsorption period, the cells were maintained at high densities with 
frequent medium changes for 1.5-2 wk  So allow virus spread. Both helper virus and A-MuLV 
stocks were prepared from 24-h harvests of exponentially growing cultures. The virus supernates 
were centrifuged for 15 rain at low speed, filtered through a 0.45-ft filter (Millipore Corp., Bedford, 
Mass.), and frozen at -70°C for subsequent use. 
For quantitative rescue experiments with lymphoid nonproducer cells, 2 × 10 ~ cells were 
resuspended directly in i ml of the helper virus preparations supplemented with 8 ~glml 
polybrene IAldrich Chemical Co., Milwaukee, Win.). After s 1.5-h adsorption period, the cells 
were collected by low speed centrifugation, washed once with i0 ml of PBS, and treated with 
0.25% trypsin, 0.2% EDTA for 7-10 rain at .~7°C. Trypsin-EDTA was removed by low speed 
centrifugation and the cells were plated in 4 ml of RPMI  medium. Subsequently, culture fluids 
were collected for virus assay at 24-h intervals. The cells were collected and replated at the initial 
cell density (5 × 1& cellslml) in fresh medium for the next collection interval. 
Virus Ass,,ys. Helper viruses were assayed on NIH/3T3 and BALB/3T3 cells by using the 
standard XC assay or by mouse S+L- assay with FG-1I) ceils (23). FG-10 assays were carried out 
by plating I × l0 s cells in 60-ram plastic dishes. 24 h later, the cells were infected with 0.5 ml of 
virus. After a 2-h adsorption period in the presence of 8 #~gjml polybrene, the cells were fed 4 ml of 
DME-CS and incubated. The S+L- plaques were visualized by hematoxylin staining 5 days 
postinfection. The titers obtained with the XC and FG-10 assays were equivalent for all the virus 
stocks (data not shown). 
Fibroblast transformation assays were used to standardize the FFU in A -MuLV stocks. Either 
1 × 10 ~ NIHf3T3 or BALB/3T3 cells, plated in 60-ram dishes 24 h previously, were infected with 
0.5-ml portions of virus. After a 2-h adsorption period in the presence of 8/ag/ml polybrene, the 
plates were fed fresh DME-CS, and incubated. Medium was changed 5 and 10 days postinfection 
and foci were scored in live cultures by using low power magnification (× 100) st 15 days 
postinfection (12). The amount of helper virus present in A-MuLV stocks was determined by using 
SC or S+L- assays. 
All helper virus and A-MuLV preparations were screened for the ability to replicate on 
xenogeneic cells. For this assay, CCL64 mink lung cells, plated 24 h previously at I × I0 ~ cellsl60 
mm dish, were infected with 0.5 ml of undiluted virus stock containing 8 ~g[ml polybrene. After 
a 2-h adsorption period, the cell~ were fed fresh DME- IFS and incubated. Cells were psssaged 
twice weekly and screened for the presence of virus by using a standard reverse tra~ascriptase 
assay 6 wk postinfection. 
Bone Marrow Transformation. Transformation of mouse bone marrow cells was carried out as 
previously described (14). Briefly, 2 × 10 s nucleated cells were plated in 35-ram dishes in 1 ml of 
RPMI medium. 1 ml of virus suspension was added to the dishes and the plates were incubated. 
I/2 ml of fresh RPMI  medium was added to the cultures 6 and 12 days postinfection. Transforma- 
tion was recognized by rapid proliferation of immature lymphoid cells in the culture fluid. 
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NAOMI ROSENBERG AND DAVID BALTIMORE 1129 
Mice. The mice used for most experiments were supplied by our breeding colony at M.I.T. 
NIH/Swiss mice were originally obtained from the Division of Research Services, National 
Institutes of Health, Bethesda, Md. BALB/cAN mice were obtained from Dr. Herman Eisen, 
M.I.T. CD-1/Swiss mice were purchased from Charles River Breeding Laboratories, Wilmington, 
Mass. For certain experiments, C57BR/cdJ mice were purchased from The Jackson Laboratory, 
Bar Harbor, Maine. 
For induction of leukemia ll animals were inoculated intraperitoneally with 0.1 ml of 0.45 ~m 
of filtered virus suspension at less than 48 h of age. Animals were observed weekly for cachexia, 
anemia, lymphadenopathy, or splenomegaly. Mice inoculated with M-MuLV clones and F-MuLV 
clones remaining disease free were sacrificed 6 mo pestinoculation. Animals inoculated with E- 
MuLV and G-MuLV were held for 15 too. Mice inoculated with all A-MuLV stocks were observed 
for 3 mo. Gross pathologic findings were noted for all animals either when illness was noted or at 
the termination of the experiments. Spleen, thymus, lymph node, liver, and any other abnormal 
tissues from representative animals were also fixed and processed for histologic examination 
according to routine procedures. 
For studies on recovery of A-MuLV from mice, several NIH/Swiss l itters were randomly mixed 
and then redivided for virus inoculation. Each mouse received equivalent doses of either A- 
MuLV(M-MuLV-1) or A-MuLV(G-MuLV). Animals were sacrificed by cervical fracture 4, 10, 15, 
and 21 days postinfection (and, in the case of A-MuLV(M-MuLV-1), when disease was evident). 
The animals were examined for evidence of disease and spleen, thymus, femur, and tibia were 
removed and frozen immediately on dry ice. Virus extracts, prepared in RPMI containing no 
serum, were made by using a dounce homogenizer or a mortar and pestle. The extracts were 
centrifuged twice at 2,500 rpm for 30 min and filtered through a 0.45-~m Millipere filter before 
infectivity studies. Protein concentration i the extracts was determined by the standard Lowry 
et al. procedure (24). 
Reverse Transcriptase Assays. 24-h supernates from exponentially growing cell cultures were 
clarified by low speed centrifugation. The supernates were then centrifuged at 100,000 g for 45 
min at 4°C. Pellets were resuspended in 0.5 ml of 0.01 M Tris-HCl (pH 7,5) and sonicated for 40 s 
in a Raytheon sonic oscillator, Raytheon Co., Portsmouth, R.I. A 50-~1 portion of the virus 
suspension was assayed for exogenous reverse transcriptase activity in 0.1 ml reaction mixture 
containing 0.05 M Tris-HC1 buffer (pH 8.3), 0.06 M NaC1, 6 mM MnC12, 0.02 M dithiothreitol, 1 
~g pely(rA) (Miles Laboratories, Inc., Kankakee, Ill.), 0.5 pg oligo(dT) (Collaborative Research, 
Inc., Waltham, Mass.), 0.05% Nonidet P-40 (Gallard Schlesinger Chemical Mfg. Corp., Carle 
Place, N.Y.), and 10 -s M [3H]dTTP (52 Ci/mmol) (New England Nuclear, Boston, Mass.). 
Results  
The tropism of the helper viruses described in Table I was determined by 
using the XC plaque assay method (21) on NIH/3T3 and BALB/3T3 cells (Table 
II). Both cloned stocks of M-MuLV produced equivalent numbers of large, clear 
plaques on the two cell lines and were therefore NB-tropic (25). The two F- 
MuLVs were of opposite tropism, one preferring NIH/3T3 cells (F-MuLV-N) and 
the other BALB/3T3 cells (F-MuLV-B). The G-MuLV stocks and E-MuLV clone 
were N-tropic, producing small, clear XC plaques preferentially on NIH/3T3 
cells. All of the viruses replicated to high titer in fibroblast cells of the 
appropriate Fv-1 genotype. None of the virus stocks had an amphotropic host 
range as determined by their inability to establish an infection in mink cells. 
The oncogenicity of helper virus preparations was determined by inoculating 
newborn mice of proper Fv-1 genotype with 0.45 ~m filtered virus stocks (Table 
III). 2 Mice were sacrificed when signs of disease were evident and gross and 
histologic examinations were conducted. Both M-MuLV-1 and M-MuLV-2 
induced disease in 96-100% of both Swiss and BALB/c mice after a 2.5-3.5-mo 
latent period. Hepatosplenomegaly and large mesenteric lymph node tumors 
2 Jolicoeur et al. J. Natl. Cancer Inst. In press. 
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1130 ABELSON VIRUS 
TABLE II 
Properties of Helper Viruses 
Virus stock 
Titer 
NIH BALB 
Growth on mink  
lung cells 
M-MuLV-1 2 x 106 1 x 106 
M-MuLV-2 2 x l0 s 1 × 106 
F-MuLV-N 4 x 105 1 x 102 
F-MuLV-B <10 1 x l0 s 
E-MuLV 1 x 104 1 × 102 
G-MuLV 3 × 105 1 x 102 
G-MuLV-1 2 × 105 8 x 102 
0.5-ml port ions of f i ltered virus di lut ions were exposed to NIH/3T3 or BALB/ 
3T3 cells plated 24 h earl ier at densit ies of 5 x 104 cells or 7.5 x 104 cells/60 
mm dish. After a 2-h v irus adsorption period, cells were fed fresh DME-CS 
and incubated. 3 days later the plates were irradiated with ultraviolet l ight 
and 1 x 106 XC cells were added. P laques were visual ized by hematoxy l in  
sta in ing.  
Growth of  v i rus stocks on mink  lung  cells was monitored by reverse transcrip-  
tase assay 6 wk postinfection. 
were prominent features of the disease and thymomas were noted in about 50% 
of the animals. Histologic examination oftumor tissue showed that the tumors 
were composed of lymphoblasts. M-MuLV-2 titrations in NIH/Swiss mice 
indicated that doses less than 6 x 103 were effective in disease induction (data 
not shown). 
F-MuLV-B and F-MuLV-N were also oncogenic. Both viruses induced dis- 
eases confined to the spleen and liver. Mesenteric and peripheral lymph nodes 
and the thymus of inoculated mice were normal. Histologic examination ofthe 
diseased tissues showed the F-MuLV-B-induced tumors to be composed of 
lymphoblasts, morphologically indistinguishable from the cells in M-MuLV- 
induced tumors. As with M-MuLV, F-MuLV-B induced a disease after a 2.5- 
3.5-mo latent period. F-MuLV-N induced disease after a short, 5-6 wk, latent 
period. The types of cells in F-MuLV-N-induced tumors have not been fully 
characterized. The virus stocks did induce disease in adult mice but did not 
induce spleen foci characteristic of Friend virus complex with the standard 9
day focus assay (26) (data not shown). 
Neither E-MuLV nor G-MuLV induced tumors in NIH/Swiss mice. Inoculated 
animals were observed for 15 mo and no gross or histologic evidence of tumors 
was noted. 
Characterization of Abelson Stocks. Two A-MuLV-transformed nonpro- 
ducer fibroblast cell lines were used to prepare A-MuLV stocks with the various 
helpers. ANN-1 cells (12), derived from NIH/3T3 cells, were used to prepare 
virus stocks with N- and NB-tropic helpers and 5H cells, derived from BALB/c 
JLS-V9 cells (27), were used to prepare virus stocks with B- and NB-tropic 
helpers. The focus-forming component of all virus stocks was monitored by 
transformation f NIH/3T3 or BALB/3T3 cells and the titers are represented as
FFU. Helper virus titers were determined by using XC or S+L- plaque assays 
and are represented as PFU. All A-MuLV stocks transformed fibroblasts of 
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NAOMI  ROSENBERG AND DAVID BALTIMORE 
TABLB I I I  
Oncogenicity ofHelper Viruses 
1131 
Titer inocu- Disease fre- 
Virus stock Mouse strain 
lated (PFU) quency 
Latent period 
Mean Range 
days 
M-MuLV-1 1 x 104 N 15/15 102 78-118 
1 x 104 B 30/31 83 77-91 
M-MuLV-2 7 x 103 N 6/6 92 72-109 
3 x I0 ~ B 6/6 109 94-128 
F-MuLV-N I × l04 N 5/6 37 34-39 
E-MuLV 3 × 104 N 0/11 - - 
G-MuLV 3 x 104 N 0/11 - - 
Neonatal mice were inoculated intraperitoneally with filtered virus stocks and observed for signs 
of disease. Animals inoculated with E-MuLV and G-MuLV were observed for 15 mo. The mouse 
strains used were either CD-1 or NIH/Swiss (N) and BALB/c (B). CD-1 and NIH/Swiss mice are 
equally susceptible to these lymphoma viruses. 
appropriate Fv-1 genotype fficiently and reflected the tropism of the helper 
virus (Table IV). The proportion of helper virus in virus stocks varied with the 
preparation but most of the virus stocks had PFU/FFU ratios of 1-5. Virus 
stocks prepared with M-MuLV-1 and ANN-1 cells and one ANN-l-grown F- 
MuLV-N stock contained virus that could replicate in mink lung cells. Occasion- 
ally, preparations made with 5H cells contained virus that could replicate on 
mink cells after long-term infection (Table IV). Xenotropic virus probably arises 
as a low level contaminant from the rescued A-MuLV nonproducer cell lines. 
Most transformed lymphoid cell lines isolated with these virus stocks do not 
release virus which grows on mink lung cells (data not shown). 
To determine the relationship between FFU and Abelson disease induction, 
an in vivo A-MuLV titration was performed initially by using A-MuLV(M- 
MuLV-2) and NIH/Swiss mice. Mice were sacrificed when cachexia, lymphade- 
nopathy, paralysis of hind limbs, or meningeal tumors evident grossly as a 
bulging of cranial bones were noted. Animals with lymphosarcomas involving 
bone marrow and peripheral lymph nodes with slight splenomegaly and normal 
thymus and mesenteric lymph nodes were scored as positive for Abelson disease. 
An inoculum of 10 ~ FFU induced disease in more than 50% of the test animals 
while only 1 of 11 mice inoculated with 5 × 102 FFU developed Abelson disease 
(Table V). 
A-MuLV prepared with the various helper viruses was then inoculated into 
newborn mice at doses expected to give a high disease frequency based on the 
A-MuLV(M-MuLV-2) titration. A-MuLV stocks prepared with both clones of M- 
MuLV induced disease efficiently in NIH/Swiss and BALB/c mice after a 3-5- 
wk latent period (Table VI). Typical Abelson lymphosarcomas, characterized by 
large tumors of peripheral lymph nodes, spine, and skull with slight splenomeg- 
aly and normal thymus, were found in these animals. Histologically, the tumors 
were composed of immature lymphoid cells. Disease after A-MuLV(F-MuLV-B) 
inoculation was similar to the syndrome observed when A-MuLV(M-MuLV) 
clones were used. The A-MuLV(F-MuLV-B) stocks were more efficient in 
BALB/c than NIH/Swiss mice. 
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1132 ABELSON VIRUS 
TABLe. IV 
Properties of A-MuL V Stocks 
Virus stock 
PFU Titer FFU Titer 
NIH BALB NIH BALB 
Growth on 
mink lung 
cells 
ANN-I(M-MuLV-I) 1 x 10 6 7 x 10 5 1 x 10 6 7 x 10 5 + 
ANN-I(M-MuLV-2) 1 x 10 6 ND* 5 x 10 5 5 x 10 5 ND 
ANN-I(F-MuLV-N) 2 x 10 5 4 x i0 ' 7 x 10 5 <I0 +/ -  
ANN-I(E-MuLV) 2 x 10 4 3 x I0 ~ 4 x 10 4 I x 10 2 - 
ANN-I(G-MuLV) 8 x 10 4 3 x 10 2 1 x 10 ~ 8 x I0' - 
5H(M-MuLV-2) 3 x l0 s 2 x i0 ~ 9 x 10 4 4 x 10 4 + 
5H(F-MuLV-B) <10 1 x I0 ~ <I0 2 × 10 5 +/ -  
0.5-ml portions of filtered virus dilutions were exposed to NIH/3T3 or BALB/3T3 cells for assay 
by the standard XC plaque test or the A-MuLV fibroblast focus assay. For the XC test, XC cells 
were added to monolayers irradiated with ultraviolet l ight 3 days postinfection and plaques 
were scored 3 days later. A-MuLV transformed foci were scored 15 days postinfection. Growth of 
virus on mink lung cells was monitored by reverse transcriptase assay 6 wk postinfection. The 
A-MuLV stocks are described by the nonproducer cell from which they were derived and, in 
parenthesis, the helper virus used for rescue. 
* ND, not done. 
NIH/Swiss mice inoculated with A-MuLV(F-MuLV-N) also developed typical 
Abelson disease (Table VI). However, in all of the mice inoculated with this 
virus stock, hepatosplenomegaly was a prominent feature of the disease. This 
type of pathology is very uncommon in Abelson disease and probably reflects 
the action of the F-MuLV-N helper virus in the preparation. The overlapping 
latent period for F-MuLV-N disease and Abelson disease makes it difficult to 
assess which cells have responded to which virus. Skull, spine, and peripheral 
lymph node tumors, characteristic of Abelson disease, and never noted in F- 
MuLV-N injected mice, were present in about 40% of the animals. The high 
titer of helper virus in the particular A-MuLV(F-MuLV-N) preparation used in 
these animal experiments may account for the high proportion of animals with 
hepatosplenomegaly. 
Mice inoculated with A-MuLV(G-MuLV) did not develop any detectable 
disease during a 3-4-mo observation period. To determine if A-MuLV(G-MuLV) 
replicates in inoculated animals, lymphoid tissues from NIH/Swiss mice injected 
with this virus stock were extracted and examined for virus by using the S+L- 
assay and the NIH/3T3 focus assay (Fig. 1). Tissues from mice inoculated with 
an equivalent amount of A-MuLV(M-MuLV-1) served as controls. The virus 
dose used, 2 × 104 FFU, induced disease in 100% of the A-MuLV(M-MuLV-1) 
inoculated mice. A-MuLV(M-MuLV-1) replicated well in the mice and as early 
as 4 days postinjection both components of A-MuLV could be detected in bones 
of the animals. Helper virus was also recovered from spleen and thymus. As the 
incubation period increased, the titer of A-MuLV increased. The higher titer of 
A-MuLV in thymus tissue observed in the tumored mice probably arises from 
large parathymic lymph node tumors in these animals. No virus was recovered 
from bone, spleen, or thymus of A-MuLV(G-MuLV) injected mice. Litter mates 
of the A-MuLV(G-MuLV) mice sacrificed in these experiments are healthy 5 mo 
postinoculation. 
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NAOMI ROSENBERG AND DAVID BALTIMORE 
TABLE V 
Oncogenicity of A-MuL V(M-MuLV-2) 
1133 
Titer inoculated Disease fre- Latent period 
PFU FFU quency Mean Range 
days 
1.5 x l0 s 5 x 104 8/8 24 21-28 
1.5 x 104 5 × l0 s 6/7 33 29-40 
3 × 10 s 1 x l0 s 3/5 75 71-78 
1.5 x l0 s 5 x 10 z 1/11 - 78 
Neonatal mice were inoculated intraperitoneally with 0.1 ml of filtered virus stock. 
Animals were sacrificed when disease was evident. Animals were observed for at 
least 5 mo. 
TABLE VI  
Oncogenicity of A-MuL V Stocks 
Titer inoculated Mouse Disease Latent period 
Virus stocks 
PFU FFU strain frequency Mean Range 
days 
ANN-I(M-MuLV-1) 1 × l0 s 2 x 104 N 4/4 30 28-30 
ND* 2 x 104 B 7/7 19 18-20 
ANN-I(M-MuLV-2) 1 x 104 5 × 103 N 8/8 37 29-43 
B ND - - 
ANN- I (F -MuLV-N)  2 × 104 4 × 103 N 11/11 41 38-55 
B ND - - 
5H(M-MuLV-2)  3 × 104 6 x 103 N 5/9 54 28-87 
B 5/5 28 23-30 
5H(F-MuLV-B) 1 x 10 ~ 3 × 104 N 1/6 30 30 
B 5/6 31 24-47 
ANN-I(G-MuLV) 8 x 103 1 × 104 N 0/14 - - 
B ND - - 
Neonatal mice were inoculated intraperitoneally with 0.1 ml of filtered virus stock. Animals 
were sacrificed when disease was evident. Animals were observed for at least 3 too. Mouse 
strains used were NIH/Swiss (N) and BALB/c (B). The A-MuLV stocks are described by the 
nonproducer cell from which they were derived and, in parentheses, the helper virus used for 
rescue. 
* ND, not done. 
Transformation of Bone Marrow Cells. To determine the effect of helper 
viruses on the ability of A-MuLV stocks to transform hematopoietic cells in 
vitro, bone marrow cells from 4- to 6-wk old mice were infected and plated in a 
quantitative agarose transformation assay. Macroscopic foci of lymphoid cells 
were counted 12 days postinfection (Table VII). The transformation frequency 
obtained with different virus preparations was standardized by the fibroblast 
FFU in the virus stocks. A-MuLV in combination with most of the helper 
viruses efficiently transformed lymphoid cells. Colonies arising in these cultures 
could routinely be established as continuous cell lines. Plating efficiency in 
most cases was 80-90% (data not shown). 
Cultures infected with A-MuLV(E-MuLV) and A-MuLV(G-MuLV) had very 
few macroscopic foci (Table VII). In more than 200 A-MuLV(E-MuLV) infected 
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FIG. 1. Recovery of A-MuLV from mice. Extracts of bone (b), spleen (s), and thymus (t) 
from mice injected with A-MuLV(M-MuLV-1) or A-MuLV(G-MuLV) were assayed for both 
components of A-MuLV in vitro. Lymph node tumors (n.t.) from terminal animals injected 
with A-MuLV(M-MuLV-1) were also examined. • (A-MuLV) indicates FFU and [] (M- 
MuLV) indicates PFU recovered in the various tissues from A-MuLV(M-MuLV-1)-injected 
mice. For mice injected with A-MuLV(G-MuLV), results are shown in one column (A/G) 
although all three tissues were assayed separately. 
cultures, three foci were observed. None of these grew independently in liquid 
culture. One macroscopic focus has been noted in a culture infected with A- 
MuLV(G-MuLV). The cells in this focus did grow independently and were 
established as a cell line. The cells appeared to be similar to other A-MuLV 
transformed lymphoid cells with respect o growth and morphologic properties. 
The cells did not produce infectious virus, but did contain the A-MuLV genome 
which could be rescued by superinfection with M-MuLV (data not shown). 
To further investigate the transformation potential of A-MuLV stocks, both 
A-MuLV(E-MuLV) and A-MuLV(G-MuLV) were used to infect mass cultures of 
bone marrow cells. In this transformation test, virus is mixed with bone marrow 
cells in liquid culture and the cells are incubated in the presence of input virus 
and any virus arising by subsequent rounds of replication. Under conditions 
where an equivalent dose of A-MuLV(M-MuLV-1) transformed 95-100% of the 
cultures, no transformation was observed in cultures infected with either A- 
MuLV(E-MuLV) or A-MuLV(G-MuLV). 
The ratio of helper virus to fibroblast focus-forming virus in different A- 
MuLV stocks varies. However, the amount of helper virus in A-MuLV stocks 
does not appear to influence the transformation potential of the virus (Table 
VI). Addition of a competent helper virus such as M-MuLV-1 to A-MuLV(G- 
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TABLE VII 
A-MuL V-Induced Transformation ofBone Marrow Cells 
1135 
Lymphoid foci/10 ~fibro- Lymphoid foci 
PFU blast FFU NIH/Swiss mar- 
Virus stock FFU row/Lymphoid OncogeniCin vivo 
foci BALB/c mar- NIH/Swiss BALB/c 
row 
ANN-I(M-MuLV-1) 6 92 48 1.7 Yes 
ANN-I(M-MuLV-2) 5 28 26 1.0 Yes 
ANN-1 (F-MuLV-N) 3 20 0.25 200 Yes 
5H(M-MuLV-2) 3 148 88 1.6 Yes 
5H(F-MuLV-B) 0.5 8 103 0.006 Yes 
ANN-I(G-MuLV) 0.7 <0.01 ND* No 
ANN-I(E-MuLV) 1.5 <0.02 ND ND 
NIH/Swiss or BALB/c mouse bone marrow was infected with A-MuLV in vitro and plated in the 
standard lymphoid cell transformation assay. Foci were scored 12 days postinfection. The A- 
MuLV stocks are described by the nonproducer cell from which they were derived and, in 
parenthesis, the helper virus used for rescue. 
* ND, not done. 
MuLV) virus at the t ime of infection did not overcome its inabil ity in transfor- 
mation (data not shown). 
As has been observed for fibroblast cells, N-tropic A-MuLV stocks preferen- 
tially transform lymphoid cells from Fv-1 "~n mice while B-tropic A-MuLV stocks 
are much more efficient on bone marrow cells from Fv-1 b~b mice (Table VII). 
NB-tropic A-MuLV stocks transform bone marrow cells from both types of mice 
at high efficiency. 
Results obtained in a different experimental  system (28) have suggested that  
Fv- l -mediated restriction does not operate in lymphoid cells. The low transfor- 
mation frequencies obtained with N- and B-tropic A-MuLV stocks on bone 
marrow cells of inappropriate Fv-1 genotype suggest hat lymphoid cell trans- 
formation is subject o the effect of the Fv-1 gene. 
Rescue of A-MuLV from Nonproducer Cells. Lymphoid nonproducer cell 
lines were isolated by removing single foci from agarose culture plates and 
adapting the cells to growth in liquid medium. Nonproducer cell lines were 
identified by the lack of reverse transcriptase-containing virus particles in the 
culture fluid. Two nonproducer cell cultures, BR48 and 2M, were readily 
superinfected with M-MuLV-2 (Table VIII). After addition of the helper virus, 
infection and release of both helper and focus-forming virus occurred within 12- 
15 h. Superinfected cultures could then be maintained as stable virus-producing 
cell lines. 
Initial attempts to make virus-producing cultures of BR48 cells by using G- 
MuLV as a helper were unsuccessful (Table VIII). A standard fibroblast 
nonproducer rescue protocol was employed, growing the superinfected cells for 
1.5-2 wk before assaying virus. More careful study revealed that G-MuLV did 
not form a stable association with lymphoid nonproducer cells. Aider superinfec- 
tion with G-MuLV, virus production of both helper and focus-forming virus 
increased for the first 48-h and then declined (Fig. 2). In cultures superinfected 
with M-MuLV-2, virus production continued in a stable fashion. After virus 
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TABLE VIII 
Superinfection of A-MuL V Transformed Nonproducer Cells 
Nonproducer Helper v irus 
Virus Replication 
PFU FFU 
BR48(Fv-1 ~j~) M-MuLV-2 1 × l0 s 8 x 10 4 
F-MuLV-N 1 x 10 3 2 x 10 2 
G-MuLV-1 9 2 
E-MuLV 0 0 
2M(Fv-1 b/b) M-MuLV-2 2 x 105 7 × 104 
F-MuLV-B 1.5 x 108 5 x 105 
C57B1/KaB 0 ND* 
Lymphoid nonproducer cell l ines were infected with helper v i ruses at an 
raoi of 0.5. After a 2-h adsorption period, cells were mainta ined  as exponen- 
t ial ly growing cultures for 10-14 days at which t ime fresh culture f luids 
were examined for the presence of PFU and FFU.  Viruses produced by 2M 
cells were assayed on BALB/3T3 cells. V iruses produced by BR48 cells were 
assayed on NIH/3T3 cells. 
* ND, not done. 
production had ceased in BR48(G-MuLV) cultures, the population could be 
reinfected with G-MuLV or M-MuLV-2 suggesting that the culture has lost 
some if not all virus expression from the initial superinfection. 
BR48 cells, an Fv-1 njn cell line, could be stably superinfected by F-MuLV-N 
but not by E-MuLV (N-tropic). 2M, an Fv-1 bib cell line, could be easily 
superinfected by both M-MuLV-2 and F-MuLV-B but not by the B-tropic C57B1/ 
KaB virus (Table VIII). G-MuLV, however, did infect a T-cell lymphoma cell 
line, L691-6, and replicated nearly as efficiently as M-MuLV-2 in these cells 
(Fig. 3). 
Discussion 
These studies have shown that A-MuLV oncogenesis and lymphoid cell 
transformation is dependent on which helper virus rescued and accompanies 
the defective A-MuLV. Three MuLVs that readily caused lymphomas on their 
own acted as efficient helpers to produce Abelson disease in vivo and lymphoid 
cell transformation i vitro. Two MuLVs that induced no detectable disease by 
themselves also failed to act as efficient helpers for lymphoid cell transformation 
in vitro and the one that was tested, A-MuLV(G-MuLV), was also inactive in 
vivo. Neither component of the A-MuLV(G-MuLV) stocks established an 
infection in the inoculated mice. For fibroblast transformation, however, all five 
helpers were equally active when normalized to their PFU content. There is, 
therefore, an important difference between the requirements for A-MuLV 
transformation of lymphoid cells and of fibroblasts. Scher (29) has observed a
similar distinction in studies with Kirsten sarcoma virus and A-MuLV. 
Transformation of fibroblasts by A-MuLV is similar to transformation of 
fibroblasts by murine sarcoma viruses in that any MuLV that can replicate on 
its own will act as an effective helper (1, 2, 5, 6, 30). What then is the 
significance of the helper specificity for lymphoid cell transformation and 
oncogenesis by A-MuLV? 
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FIG. 2. Replication of virus in A-MuLV-transformed lymphoid nonproducer cells. BR48 
cells were infected with M-MuLV and G-MuLV at an moi of 0.1. Virus in the culture fluids 
was monitored at intervals postinfection by using standard assays. 
Two hypotheses are possible. One is that the helper is needed for effective 
penetration of the A-MuLV genome and that lymphoid target cells have 
receptors that distinguish the competent helpers from the incompetent ones. 
The other hypothesis that the helper plays an intracellular role in initiating 
or maintaining the transformation. 
The penetration hypothesis supported by the inability of an added compe- 
tent helper virus to elicit lymphoid transformation byan incompetent A-MuLV 
stock. Other explanations of this result, however, are possible and further 
experiments in this area are needed. 
As a test of the penetration hypothesis, we examined the ability of A-MuLV 
transformed nonproducer lymphoid cells to be infected by G-MuLV and M- 
MuLV. Both viruses established infections in the A-MuLV-transformed cells 
therefore, it can be argued, that at least after transformation the cells have 
receptors for both viruses. We cannot est the cells before infection because we 
cannot make a pure culture of target cells. A further argument against he 
penetration hypothesis i the ability of G-MuLV and M-MuLV pseudotypes 
with vesicular stomatitis virus to infect he A-MuLV-transformed nonproducer 
cells with equal efficiency (P. Besmer et al., unpublished results). 
The possibility that the "helper" may play a critical, on-going role in the 
transformation process receives ome support from our studies of particle 
production by the A-MuLV-transformed lymphoid cell lines. Some of these lines 
are totally nonproductive but a majority do produce a noninfectious particle (A. 
Shields et al., unpublished results). This particle has a major internal protein 
closely related to that of M-MuLV suggesting that the M-MuLV genome may be 
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FIa. 3. Replication of helper virus in L691-6 thymoma cells. L691-6 cells were infected 
with M-MuLV-1 and G-MuLV at an moi of 0.1, Virus in culture fluids was monitored at 
intervals postinfection by using standard assays. 
present in most of the lymphoid transformants. Nucleic acid hybridization 
experiments will be able to assess whether all transformants might contain 
some or all of the M-MuLV genome. If the genome is present, it could contribute 
to maintaining the transformed state. This possibility is not without precedent: 
certain murine sarcoma viruses only transform in the presence of a helper virus 
(6, 23). 
The transitory production of virus after G-MuLV infection of the A-MuLV- 
transformed nonproducer cells (Fig. 2) is not understood. The loss of infectivity 
is so rapid that overgrowth of initially uninfected cells is an unlikely explana- 
tion. It seems that G-MuLV, although it can initiate infection, cannot stably 
maintain the infected state and whether the G-MuLV provirus can even 
integrate is not known. The inability of G-MuLV to stably infect lymphoid 
nonproducer cells does not reflect an inability of this virus to infect all lymphoid 
cells, however, because this virus replicates nearly as well as M-MuLV-2 in 
L691 lymphoma cells. This inability of G-MuLV to maintain a productive 
infection of the A-MuLV-transformed cells may be an explanation of its inability 
to act as an effective helper for A-MuLV transformation. 
The inability of E-MuLV, another inefficient helper, to stably infect lymphoid 
nonproducer cells supports a correlation between a virus' inability to help A- 
MuLV transform lymphoid cells and its inability to stably associate with 
lymphoid nonproducer cells. Although the helper efficiency of C57B1/KaB virus 
has not been determined, the virus is fihrotropic and nononcogenic n C57B1/Ka 
mice (22). Thus, the inability of this virus to stably infect 2M cells probably also 
fits this pattern. 
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The correlation between the oncogenicity of a replication-competent MuLV 
and its ability to act as an efficient helper is striking. This could suggest hat 
the helper virus is providing a critical leukemogenic function in the transfor- 
mation process. Thus, the data might be reinterpreted by saying that A-MuLV 
is acting as a helper for the replication competent MuLV in producing the 
Abelson disease. The Abelson virus would then function to alter the cellular 
specificity of the leukemogenic virus, e.g. M-MuLV, and allow it to transform 
more immature lymphoid cells than those usually affected by that virus (17). 
These speculations may seem premature but they serve to focus attention on 
the difference between lymphoid cell transformation a d fibroblast cell transfor- 
mation. Fibroblast ransformation may be a relatively simple process whereby 
a single gene product establishes control of cellular growth but at present 
leukemia virus transformation has properties that suggest more complex 
interactions. 
Summary  
Abelson murine leukemia virus (A-MuLV)-transformed fibroblast nonpro- 
ducer cells were used to prepare A-MuLV stocks containing a number of 
different helper viruses. The oncogenicity of the A-MuLV stocks was tested by 
animal inoculation and their ability to transform normal mouse bone marrow 
cells was measured in vitro. All of the A-MuLV stocks transformed fibroblast 
cells efficiently. However, only A-MuLV stocks prepared with helper viruses 
that are highly oncogenic were efficient in vivo and in vitro in hematopoietic 
cell transformation. In addition, inefficient helpers did not establish a stable 
infection in lymphoid nonproducer cells. Thus, helper virus has a more central 
role in lymphoid cell transformation than in fibroblast cell transformation. 
We thank Daniel Clark for excellent technical assistance. 
Received for publication 9 November 1977. 
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